首页> 外国专利> METHOD FOR PREDICTING DISEASE-FREE SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

METHOD FOR PREDICTING DISEASE-FREE SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

机译:自体造血干细胞移植后多发性骨髓瘤患者无病生存的预测方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to oncohematology, and can be used for prediction of recurrence free survival developing in patients with multiple myeloma after autologous hematopoietic stem cells. Method for prediction of recurrence free survival in patients with multiple myeloma following autologous transplantation of hematopoietic stem cells (ATGSK) includes flow cytometry and estimation of relative content of one of lymphocyte populations using its threshold value. Proposed method after apheresis procedure, before transplantation in patient's apheresis product relative number of CD45+CD19+ b-cells is determined, and if CD45+CD19+ b-cell count is more than 2.5%, shorter period-free survival after ATGSK is predicted, and if CD45+CD19+ b-cells count is less than 2.5%, extended recurrence free survival period after ATGSK is predicted.;EFFECT: simplified method for prediction of recurrence-free survival in patients with multiple myeloma after ATGSK.;1 cl, 1 dwg
机译:发明领域本发明涉及肿瘤血液学,并且可用于预测自体造血干细胞后多发性骨髓瘤患者无复发生存的发展。预测自体移植造血干细胞后多发性骨髓瘤患者无复发生存的方法包括流式细胞术和使用其阈值估算淋巴细胞群之一的相对含量。提议的单采血液分离程序之后,在患者的单采血液分离产物移植之前,确定CD45 + CD19 + b细胞的相对数量,以及是否确定CD45 + CD19 + b细胞计数超过2.5%,预测ATGSK后的无周期生存期较短,如果CD45 + CD19 + b -细胞计数低于2.5%,可预测ATGSK后无复发生存期延长。;效果:简化的ATGSK后多发性骨髓瘤患者无复发生存期预测方法; 1 cl,1 dwg

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号